1. Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM). Référentiel des ATU nominatives. 2017. https://www.ansm.sante.fr/Activites/Autorisations-temporaires-d-utilisation-ATU/Referentiel-des-ATU-nominatives/Referentiel-des-ATU-nominatives. Accessed 14 Nov 2019.
2. Hsu WH. Toxicity and drug interactions of levamisole. JAVMA. 1980;176:1166–9.
3. EMA. https://www.ema.europa.eu/en/documents/mrl-report/levamisole-summary-report-1-committee-veterinary-medicinal-products_en.pdf. Accessed 14 Nov 2019.
4. European Monitoring Centre for Drugs and Drug Addiction. Recent changes in Europe’s cocaine market. Results from an EMCDDA trendspotter study, 2018. https://www.emcdda.europa.eu/system/files/publications/10225/2018-cocaine-trendspotter-rapid-communication.pdf. Accessed 14 Nov 2019.
5. Raymon LP, Isenschmid DS. Letter to the editor: The possible role of levamisole in illicit cocaine preparations. J Anal Toxicol. 2009;33:620–2.